Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioconjug Chem ; 16(3): 582-7, 2005.
Article in English | MEDLINE | ID: mdl-15898725

ABSTRACT

A trifunctional bioconjugate consisting of the SV40 nuclear localization signal (NLS) peptide, an aliphatic triamine ligand, and the DNA intercalating pyrene has been synthesized and quantitatively labeled with [(99m)Tc(OH(2))(3)(CO)(3)](+). The radiotoxicity of the resulting nucleus-targeting radiopharmaceutical on B16F1 mouse melanoma cells has been investigated to evaluate the activity of Auger and Coster-Kronig electrons on the viability of cells. We found a dose-dependent significant radiotoxicity of the nucleus-targeting radiopharmaceutical clearly related to the low energy decay of (99m)Tc. These principal results imply a possible therapeutic strategy based on the use of the low-energy Auger electron-emitting (99m)Tc radionuclide attached to nucleus-targeting molecules and comprising an intercalator. Highly efficient DNA targeting vectors could complement the usual role of (99m)Tc in diagnostic applications. The Auger electrons emitted by the (99m)Tc nuclide induce DNA damage leading ultimately, through a mitotic catastrophe pathway, to necrotic cell death. Non-DNA-targeting (99m)Tc complexes display much lower radiotoxicity.


Subject(s)
Intercalating Agents/pharmacokinetics , Intercalating Agents/toxicity , Nuclear Localization Signals/chemistry , Nuclear Localization Signals/pharmacokinetics , Organotechnetium Compounds/toxicity , Animals , Cell Line, Tumor , Cell Nucleus/metabolism , Dose-Response Relationship, Radiation , Intercalating Agents/chemistry , Mice , Molecular Structure , Organotechnetium Compounds/chemistry , Organotechnetium Compounds/pharmacokinetics
2.
Neurobiol Dis ; 18(3): 656-68, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15755691

ABSTRACT

Point mutations affecting PMP22 can cause hereditary demyelinating and dysmyelinating peripheral neuropathies. In addition, duplication and deletion of PMP22 are associated with Charcot-Marie-Tooth disease Type 1A (CMT1A) and Hereditary Neuropathy with Liability to Pressure Palsy (HNPP), respectively. This study was designed to elucidate disease processes caused by misexpression of Pmp22 and, at the same time, to gain further information on the controversial molecular function of PMP22. To this end, we took advantage of the unique resource of a set of various Pmp22 mutant mice to carry out comparative expression profiling of mutant and wild-type sciatic nerves. Tissues derived from Pmp22-/- ("knockout"), Pmp22tg (increased Pmp22 copy number), and Trembler (Tr; point mutation in Pmp22) mutant mice were analyzed at two developmental stages: (i) at postnatal day (P)4, when normal myelination has just started and primary causative defects of the mutations are expected to be apparent, and (ii) at P60, with the goal of obtaining information on secondary disease effects. Interestingly, the three Pmp22 mutants exhibited distinct profiles of gene expression, suggesting different disease mechanisms. Increased expression of genes involved in cell cycle regulation and DNA replication is characteristic and specific for the early stage in Pmp22-/- mice, supporting a primary function of PMP22 in the regulation of Schwann cell proliferation. In the Tr mutant, a distinguishing feature is the high expression of stress response genes. Both Tr and Pmp22tg mice show strongly reduced expression of genes important for cholesterol synthesis at P4, a characteristic that is common to all three mutants at P60. Finally, we have identified a number of candidate genes that may play important roles in the disease process or in myelination per se.


Subject(s)
Gene Dosage , Myelin Proteins/genetics , Peripheral Nervous System Diseases/genetics , Point Mutation , Animals , Animals, Newborn , Gene Expression Regulation/genetics , Genes, cdc/physiology , Mice , Mice, Knockout , Mice, Transgenic , Myelin Proteins/biosynthesis , Myelin Proteins/physiology , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/pathology
3.
Dev Biol ; 250(1): 168-80, 2002 Oct 01.
Article in English | MEDLINE | ID: mdl-12297104

ABSTRACT

The transcription factor Erm is a member of the Pea3 subfamily of Ets domain proteins that is expressed in multipotent neural crest cells, peripheral neurons, and satellite glia. A specific role of Erm during development has not yet been established. We addressed the function of Erm in neural crest development by forced expression of a dominant-negative form of Erm. Functional inhibition of Erm in neural crest cells interfered with neuronal fate decision, while progenitor survival and proliferation were not affected. In contrast, blocking Erm function in neural crest stem cells did not influence their ability to adopt a glial fate, independent of the glia-inducing signal. Furthermore, glial survival and differentiation were normal. However, the proliferation rate was drastically diminished in glial cells, suggesting a glia-specific role of Erm in controlling cell cycle progression. Thus, in contrast to other members of the Pea3 subfamily that are involved in late steps of neurogenesis, Erm appears to be required in early neural crest development. Moreover, our data point to multiple, lineage-specific roles of Erm in neural crest stem cells and their derivatives, suggesting that Erm function is dependent on the cell intrinsic and extrinsic context.


Subject(s)
DNA-Binding Proteins/physiology , Neural Crest/cytology , Stem Cells/cytology , Transcription Factors/physiology , Animals , Cell Differentiation , Cell Division , Cell Line , Cell Lineage , Cells, Cultured , DNA-Binding Proteins/genetics , Female , Gene Expression , Humans , Male , Mutagenesis , Neuroglia/cytology , Protein Structure, Tertiary , Rats , Transcription Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...